SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-17-004000
Filing Date
2017-05-09
Accepted
2017-05-09 16:31:17
Documents
63
Period of Report
2017-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q acrs-20170331x10q.htm 10-Q 1174015
2 EX-10.1 acrs-20170331ex10137e18d.htm EX-10.1 136402
3 EX-31.1 acrs-20170331ex311b45f04.htm EX-31.1 14081
4 EX-31.2 acrs-20170331ex3129bb3a2.htm EX-31.2 14067
5 EX-32.1 acrs-20170331ex321cce7c6.htm EX-32.1 10664
  Complete submission text file 0001558370-17-004000.txt   5275698

Data Files

Seq Description Document Type Size
6 EX-101.INS acrs-20170331.xml EX-101.INS 1162323
7 EX-101.SCH acrs-20170331.xsd EX-101.SCH 35656
8 EX-101.CAL acrs-20170331_cal.xml EX-101.CAL 39097
9 EX-101.DEF acrs-20170331_def.xml EX-101.DEF 136546
10 EX-101.LAB acrs-20170331_lab.xml EX-101.LAB 377010
11 EX-101.PRE acrs-20170331_pre.xml EX-101.PRE 265143
Mailing Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355
Business Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355 484-321-5554
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37581 | Film No.: 17826892
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences